RT Book, Section
A1 Paulmichl, Markus
A1 Maliepaard, Marc
A1 Papaluca, Marisa
A1 Grimstein, Christian
A2 Bertino, Joseph S.
A2 DeVane, C. Lindsay
A2 Fuhr, Uwe
A2 Kashuba, Angela D.
A2 Ma, Joseph D.
SR Print(0)
ID 56875471
T1 Chapter 4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA
T2 Pharmacogenomics: An Introduction and Clinical Perspective
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-174169-9
LK accesspharmacy.mhmedical.com/content.aspx?aid=56875471
RD 2024/04/19
AB Review  and  discuss  the  regulatory  considerations  for  pharmacogenomics  set  forth  by  the  European  Medicines  Agency  (EMA).Review  and  discuss  the  regulatory  considerations  for  pharmacogenomics  set  forth  by  the  US  Food  and  Drug  Administration  (FDA).Understand  how  these  regulatory  agencies  have  similarities  and  differences  in  their  rules  and  application.